Actinium Pharmaceuticals Inc (ATNM)

$1.74 +0.03 (1.75%)
Market Cap 54.28M
Revenue (ttm) 0.00
Net Income (ttm) -38.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 123,000
Avg Vol 315,564
Day's Range N/A - N/A
Shares Out 31.20M
Stochastic %K 87%
Beta -0.53
Analysts Strong Sell
Price Target $5.00

Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 677 3870
Address:
100 Park Avenue, 23rd Floor, New York, United States
Pinto72
Pinto72 Aug. 24 at 4:49 AM
$ATNM Crada🚀🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣🤣🤣 $800 per share post AdHoc🚀🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!!🚀🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣🤣🤣 HELLOOOOOOOO, @buynhold1 !!!!!! BANKRUPTCY = AS SOON!!!!!!!🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣🤣🤣
0 · Reply
TapeTone
TapeTone Aug. 23 at 6:17 AM
$ATNM Actinium Pharmaceuticals is a clinical stage oncology company with high-risk drug development programs
0 · Reply
johnny4cures
johnny4cures Aug. 23 at 5:13 AM
$ATNM Why not have a crada with Iomab-B. They do not think outside the box
0 · Reply
Pinto72
Pinto72 Aug. 22 at 8:07 PM
$ATNM AAVIE!!!!🚀🚀🚀🚀🤣🤣🤣🤣🤣
0 · Reply
SageSpirits
SageSpirits Aug. 22 at 4:14 PM
$ATNM are we there yet?
0 · Reply
1Hamfredbuttlington
1Hamfredbuttlington Aug. 22 at 2:16 PM
$ATNM wow gap up...SS messed the bed?
0 · Reply
gooddoggie
gooddoggie Aug. 22 at 8:44 AM
$ATNM You don’t care for the pudding Mr Simpson?
1 · Reply
WatchlistDrifter
WatchlistDrifter Aug. 22 at 4:42 AM
$ATNM Actinium Pharmaceuticals is a clinical stage oncology company with radioimmunotherapy platforms high risk high reward based on trial outcomes
1 · Reply
johnny4cures
johnny4cures Aug. 22 at 4:09 AM
$ATNM
1 · Reply
johnny4cures
johnny4cures Aug. 22 at 4:01 AM
$ATNM Mono, combo, sequential, ATNM-400 in the non-psma
0 · Reply
Latest News on ATNM
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Jul 31, 2025, 8:30 AM EDT - 23 days ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 23, 2025, 11:30 AM EDT - 2 months ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

May 22, 2025, 5:45 AM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

May 15, 2025, 1:43 PM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 14, 2025, 1:26 PM EDT - 3 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

May 6, 2025, 8:45 AM EDT - 3 months ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Apr 30, 2025, 7:25 AM EDT - 4 months ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:30 AM EDT - 4 months ago

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 4 months ago

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Apr 24, 2025, 5:00 AM EDT - 4 months ago

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 19, 2025, 8:20 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Apr 17, 2025, 5:45 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

Apr 16, 2025, 10:01 AM EDT - 4 months ago

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

IBTA

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

Mar 28, 2025, 11:57 AM EDT - 5 months ago

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Mar 27, 2025, 8:45 AM EDT - 5 months ago

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Mar 25, 2025, 6:00 AM EDT - 5 months ago

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

Mar 24, 2025, 4:15 PM EDT - 5 months ago

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy

Mar 20, 2025, 8:00 AM EDT - 5 months ago

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

Mar 19, 2025, 8:30 AM EDT - 5 months ago

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

Pinto72
Pinto72 Aug. 24 at 4:49 AM
$ATNM Crada🚀🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣🤣🤣 $800 per share post AdHoc🚀🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!!🚀🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣🤣🤣 HELLOOOOOOOO, @buynhold1 !!!!!! BANKRUPTCY = AS SOON!!!!!!!🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣🤣🤣
0 · Reply
TapeTone
TapeTone Aug. 23 at 6:17 AM
$ATNM Actinium Pharmaceuticals is a clinical stage oncology company with high-risk drug development programs
0 · Reply
johnny4cures
johnny4cures Aug. 23 at 5:13 AM
$ATNM Why not have a crada with Iomab-B. They do not think outside the box
0 · Reply
Pinto72
Pinto72 Aug. 22 at 8:07 PM
$ATNM AAVIE!!!!🚀🚀🚀🚀🤣🤣🤣🤣🤣
0 · Reply
SageSpirits
SageSpirits Aug. 22 at 4:14 PM
$ATNM are we there yet?
0 · Reply
1Hamfredbuttlington
1Hamfredbuttlington Aug. 22 at 2:16 PM
$ATNM wow gap up...SS messed the bed?
0 · Reply
gooddoggie
gooddoggie Aug. 22 at 8:44 AM
$ATNM You don’t care for the pudding Mr Simpson?
1 · Reply
WatchlistDrifter
WatchlistDrifter Aug. 22 at 4:42 AM
$ATNM Actinium Pharmaceuticals is a clinical stage oncology company with radioimmunotherapy platforms high risk high reward based on trial outcomes
1 · Reply
johnny4cures
johnny4cures Aug. 22 at 4:09 AM
$ATNM
1 · Reply
johnny4cures
johnny4cures Aug. 22 at 4:01 AM
$ATNM Mono, combo, sequential, ATNM-400 in the non-psma
0 · Reply
Pinto72
Pinto72 Aug. 21 at 7:39 PM
$ATNM LOMAB🚀🚀🚀🤣🤣🤣🤣
0 · Reply
excobito
excobito Aug. 21 at 7:14 PM
$ATNM Random friday spike coming a day early? :)
0 · Reply
johnny4cures
johnny4cures Aug. 21 at 6:00 PM
$ATNM This part
2 · Reply
Arcides
Arcides Aug. 21 at 5:48 PM
$ATNM forming what looks like first base, above 200dma, volume is completely dried.
0 · Reply
resume777
resume777 Aug. 21 at 12:16 PM
$ATNM 2H2025: Solid Tumors (HNSCC, NSCLC), Actimab‑A + PD‑1 inhibitors Deplete MDSCs, enhance checkpoint efficacy; proof-of-concept by end of 2025 Proof of concept clinical data from sickle cell disease trial at Columbia University 2H2025 Commercial CAR-T initiated at UTSW, data expected in 2H2025 1H2026: Actimab-A, Venetoclax and ASTX-727. Study originally planned to start July 2025 and shifted to April 2026.
3 · Reply
Snookville
Snookville Aug. 21 at 12:16 PM
$ATNM Seth its time to turn your life around bruddah. We've been here before and we can help you out. 🤙
0 · Reply
CleanMoney
CleanMoney Aug. 21 at 11:29 AM
$ATNM Watching TV this morning. Ad for the Think Equity Conference (Oct. 30) came on. ATMN logo popped on screen….amongst others. Did raise the pulse for a brief moment.
0 · Reply
Pinto72
Pinto72 Aug. 21 at 4:31 AM
$ATNM BANKRUPTCY AS SOON!!!!🚀🚀🚀🚀🚀🚀📉📉📉📉📉🤣🤣🤣🤣🤣🤣 eXtReEmLeE bUlLiSh!!!!!!
0 · Reply
yellowjacker
yellowjacker Aug. 20 at 11:49 PM
$ATNM Back in April 5 insiders did a conversion. They may have been warrants. I do think the lack of stock ownership is weak on their part. Exspecially, as long as they have been insiders.
1 · Reply
gbtrade
gbtrade Aug. 20 at 11:29 PM
$ATNM Any ideas on why the timing of Seth cashing in? Why now? Something going on behind the scenes?
1 · Reply
gooddoggie
gooddoggie Aug. 20 at 9:50 PM
$ATNM Here’s the average underwater ATNM investor upon hearing that Seth got performance options:
0 · Reply
gooddoggie
gooddoggie Aug. 20 at 9:10 PM
$ATNM Heck, if Seth can lead us down another 70% we will up it to 200,000 shares.
1 · Reply